Business Planning Manager H/F Job

Date: September 21, 2011
Location: Issy Les Moulineaux, FRJob Category: MarketingLocation: Issy Les Moulineaux, FRJob ID: 763546-64418Division: Marketing
Looking for a responsible position within an innovative company?

M & O Division (Marketing & Operations) is seeking a Business Planning Manager H / F Its main role will be to understand, adapt and implement the process of measuring performance and to assist the various marketing teams in monitoring their investments and to the extent the performance of their campaigns.
Referring to Director of Business Planning and Operations, he / she will work closely with the teams and marketing managers of the subsidiary as well as financial managers. He / she will (e) the implementation of marketing planning and monitoring operations at a time, budgets and performance of different marketing investments in terms of business objectives.
This person will play a key role in the deployment and adoption of investment monitoring platform that accompany the four phases of the marketing campaign management: Planning, Execution, Management Responses, Reporting.

Main activities

Analysis and measurement of the performance of marketing activities (40%)

Deploy and develop the use of tools and processes for measuring and understanding of marketing performance (Return On Marketing Investment (ROMI)) with the marketing teams, ensuring communication of these results particularly in the context of the Executive Marketing Council
- Follow up on the scorecard metrics marketing - role of consulting with officials from metric
- Define the overall pattern of performance measurement in collaboration with the director of communications.
- To ensure a standardized approach (taxonomy and processes) of performance measurement and return on investment in all marketing groups
- Ensure effective measure ROI of marketing campaigns: to develop reporting and analysis to support decisions of the various marketers
- Ensure the preparation of quarterly marketing journals: allocation of investments by marketing objectives, priorities for business (initiatives, the scorecard metrics, competitive focus ...), analysis of campaign performance by segment, audience, activities ...
- Contribute to achieving the objectives of the marketing scorecard
Metric impacted: generation and optimization opportunities

Management tools and processes of marketing campaigns (20%)

- Ensure compliance of local processes with global guidelines: Develop monitoring tools to ensure consistency and identify corrective action plans
- Training: provide knowledge of processes and tools by the people marketing
- Develop a culture of marketing performance measurement
- Representing France in the reflection and the development of tools to measure ROI.

Monitoring of planning and marketing expenses (30%)

- Planning of the marketing budget: distribution and allocation of budgets in the tools in accordance with the marketing plan.
- Ensure compliance with the budget rate: financial forecasts, fences, budgetary decisions in relation to the BPO, marketers and finance.
- To develop all the reports and tools for decision support for marketing council
Metric impacted: Quarterly Forecast Accuracy (Respect the forecast marketing expenses)

Communication activities Business Planning and Operations (10%)

- Management and communication of the timing of marketing operations
- Support the organization of meetings of division
- Document Management Division

Profile

- 3 years experience marketing
- Graduate (e) business school, masters in marketing
- Data analysis, reporting, measuring return on investment ...
- Ability to synthesize
- Knowledge of international organizations
- Passion for new technologies
- Good interpersonal and communication skills
- Fluent English - Good level of French

Proxi-Business Launches Comprehensive picking

Compatible with most platforms existing e-commerce, software Proxi-Picking aims to optimize the picking in the store. It is based on new technologies in real-time location-based products and route planning.
Already in the publishing platform e-commerce, with solutions and Proxi Proxi-Store-Shop, the French company Proxi-Business has just developed a new application for inventory management. Especially in the preparation of orders. Called Proxi-Picking, it is "intended to distributors involved in all types of stores," said Olivier Bourgeois, CEO of Proxi-Business, by noting that "the specifics of the outlet are easily configured in the solution."
Development of this new solution, Proxi-Business has received a grant from OSEO on the basis of innovation. Indeed, if there are already many software warehouse management or control - respectively called WMS ("Warehouse Management Systems") and WHO ("Order Management Systems") - the systems are tailored to the stores for their many rarer.
According to Olivier Bourgeois, this lack is due to the specificity of the stores: "Built for the sale, the stores do not, contrary to the warehouses, markings to indicate locations. And their stocks move very regularly, n is not the case in the warehouse. "
Find products
Already compatible with several e-commerce software (Magento, PrestaShop ...), Proxi-picking implements three major technologies to meet the expectations of the stores. The first, geolocation product "can geotag all products of the store and see those who were displaced ...", says the CEO of Proxi-Business. It's not very complicated: with a PDA or a "scannette" it would only take two days to scan and record in the database all the products of a store with about 50,000 references.
The second innovation of Proxi-Picking, related to the calculation of routes, through a mapping or a model of the entire area of ​​the store. An operation that would be as accessible to all types of users. Everyone can position the rays by simple "click and drop" (an estimate of the size of each beam is automatically proposed based on the number of references seizures).
These settings made, the software calculates the preparation time by the number of orders and the number of processors available. And after four "modes" of operation: single-zone, multi-zone, single-or multi-control commands. To support the manager to rely on data to make the best decisions, knowingly. "Everyone is free to choose the route best suited to processors at a given time ...", reassures Olivier Bourgeois.

BioAlliance Pharma SA: First-half 2011 and advanced society

• Crossing milestones in the progress of orphan products in clinical oncology.• Strengthening of the major cash to fund R & D programs, thanks to the successful capital increase in August.• Optimization of business partnerships international Loramyc ®.PARIS - (BUSINESS WIRE) - Regulatory News:
"The company will be able to continue its international growth with a renewed Board of Directors since July. ". BioAlliance Pharma SA (Paris: BIO) (Euronext Paris - BIO), a company dedicated to cancer treatment and supportive care, today announced its consolidated financial results for the six months ended 30 June 2011 and the main advances obtained recently.
• A first milestone was reached in the development of orphan product leader Livatag ®:◦ presentation of positive Phase II showing a doubling of median survival compared to standard therapy in primary liver cancer,◦ acceptance in early September of the clinical trial phase III by Afssaps, to confirm the clinical relevance of Livatag ®. The announced schedule is confirmed with a start of this pivotal study in 2012.• The AMEP Biotherapy ® showed a good tolerance and a clear signal of efficacy in humans through a first phase I trial by local metastatic melanoma. These preliminary results will accelerate as a result of its clinical development systemically (innovative program funded by OSEO).• The Company has optimized its partnerships with Loramyc ® including:◦ signed a marketing license agreement in Japan with Sosei Co. Ltd.. for a total of $ 18.5m in stages and royalties on future sales significant, with an initial payment of $ 3 million already received.◦ resume marketing rights in the United States to the Company by Strativa, because of its recent shift to generics, this without significant financial impact. The company immediately began an active search for a new trading partner in the U.S. with assets, Oravig ®, registered with the FDA in 2010.• Finally, the company is finalizing the application files for registration of Sitavir in recurrent herpes labialis, seen in a future filing with the U.S. and European agencies."These significant advances in the first half are the result of our commitment to value assets at the stage of BioAlliance commercial partnerships with the most appropriate and with developing products that meet an unmet need. EIles demonstrate the quality of work teams BioAlliance who can find the acceleration plan appropriate to the record, "said Judith Greciet, CEO of the Company. "The company will be able to continue its international growth with a renewed Board of Directors since July. ".
Analysis of the results of the first half of 2011

               Consolidated financial statements (IFRS)in thousands of euros
    30/06/2011 30/06/2010Recurring revenue / License AgreementsNon-recurring revenue / License Agreements
Other Revenue *
    1019151
10
    55520,181
621
 Operating expenses

  Including investment in R & D

  Including non-recurring extraordinary charges
    (9.936)(4.017)
(1.376)
    (10.977)(3.608)
(1.161)
 Operating income (8 757) 10 380Net income (8 750) 10 583
* Mainly derived from the direct use in France in 2010
The company is growing its recurring revenue: product purchases by trading partners as well as royalties on their sales donated to BioAlliance exceeded the one million euros in the first half, doubling compared to 2010. Variability of revenue is also linked to the presence of non-recurring items related to international licensing agreements.
During the first half of 2011, BioAlliance has limited its overall expenses while maintaining continued investment in its programs of R & D mainly phase II trial of clonidine Lauriad ® in severe mucositis, Phase I trial of AMEP ® in invasive melanoma, and the industrial development of Sitavir.
Net income ended 30 June 2011 was - 8750 euros. In the first half 2010, net income was directly related to obtaining registration of Oravig ® in the United States, which gave rise to an exceptional product license (milestone).
Cash at 30 June 2011 amounted to 14.2 million euros against 20.9 million euros at December 31, 2010. Most of the cash burn in the first half came from R & D as well as general and administrative expenses.
The capital increase launched on July 1, oversubscribed, was conducted for a net amount of 15.9 million euros, it will accelerate the development program Livatag ® and strengthen its portfolio of orphan drugs.
"Our level of cash now estimated at around € 30 million, gives us the financial strength to ensure our strategic growth plan, particularly our R & D programs in the short and medium term." Said Nicolas Fellmann, CFO.
Introductory meeting and conference call (in English) to financial analysts
BioAlliance will meet Thursday, September 22 at 9 am at its head office from 49 boulevard Martial Valin, Paris 15 ° (France). A conference call in English will be held at 11:30 (Paris time - GMT +1). The numbers and codes to call are listed below, and the number of replay.

   From France and abroad: +33 (0) 1 70 77 09 37For replay of the call, dial +33 (0) 1 72 00 15 00 274 ​​171 # then

The Company announced today that it made available to the public and filed with the AMF's Interim Financial Report 30 June 2011. The interim financial report includes the consolidated financial statements at 30 June 2011 and is available on the website of the Company at http://www.bioalliancepharma.com, under the heading "Regulatory Information".
The interim financial statements were reviewed by the auditors and approved by the Board of Directors September 21, 2011.
About BioAlliance
Company dedicated to specialty products and orphan products in the treatment of cancer and supportive care, with an approach based on drug resistance, BioAlliance designs and develops innovative drugs mainly target hospital and drugs in rare diseases or orphaned. Founded in 1997 and introduced on the market of Euronext Paris in 2005, the company aims to become a leading player in these areas, making the link between innovation and patient needs. She holds the key skills to identify, develop and register drugs in Europe and the United States, she says their marketing to a network of international trading partners located in the hospital.
Its targeted approaches in areas where medical needs are insufficiently met contribute to the fight against drug resistance and improve the health and quality of life for patients.
For more information, visit the website at www.bioalliancepharma.com BioAlliance
BioAlliance has developed an advanced product portfolio:Specialty ProductsLoramyc ® / ® Oravig (oropharyngeal candidiasis in immunocompromised patients): Recorded in 28 countries (Europe, US, Korea)Sitavir ® (herpes labialis): positive Phase III (final results), while recordingFentanyl LauriadTM (Chronic pain in cancer patients): positive preliminary clinical results of Phase IOrphan products in oncologyLivatag ® (hepatocellular carcinoma): Agreement Afssaps for entry into phase IIIClonidine LauriadTM (mucositis post-chemotherapy and radiotherapy in head and neck cancer): Phase IIBiotherapy AMEP ® (invasive metastatic melanoma): Phase I
Warning
This press release contains expressly or implicitly certain forward-looking statements concerning BioAlliance Pharma SA and its business. These statements involve certain known and unknown risks, uncertainties and other factors that could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ materially from results, financial conditions , performance or achievements expressed or implied by such forward-looking statements. BioAlliance providing this communication as of this date and does not undertake to update forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

Traitement des commandes : DX Group (UK) augmente la cadence et traite 20 000 formulaires par semaine avec ITESOFT

PARIS--(BUSINESS WIRE)--DX Group (DX), le plus grand opérateur indépendant en logistique du Royaume Uni et d'Irlande, a choisi ITESOFT (Paris:ITE) pour automatiser le traitement des documents inhérents à son processus de commandes clients.
DX traite environ un million de bordereaux de transport, d'expédition et de bons de livraison par an. Jusqu'à présent la saisie des informations clés de ces documents vers un système de gestion financier se faisait manuellement. DX désirait réviser ce processus extrêmement lourd afin d’améliorer le traitement des informations propres à la facturation et d’optimiser ses flux de trésorerie. Souvent manuscrits, ces documents de formes très variées arrivent la plupart du temps froissés et pliés ce qui complique leurs traitements.
ITESOFT.FreeMind Enterprise relève ces défis et permettra à DX d'extraire automatiquement les informations clés améliorant par là-même l'efficacité du service de recouvrement des factures.
"Nous souhaitions fluidifier le traitement des commandes, tâche inefficace de saisie manuelle jusque-là. Nous nous sommes donc tournés vers le marché des solutions de capture à la recherche d’une solution capable de s'adapter à nos formulaires existants, de maximiser les taux de reconnaissance de caractère, de grandement améliorer notre vitesse de traitement et enfin de réduire les coûts. ITESOFT nous a proposé une solution souple et intelligente, qui a répondu à toutes nos exigences" explique Ian Pain, Directeur Financier de DX Group.
DX est le plus grand opérateur indépendant de logistique au Royaume-Uni, offrant à une clientèle professionnelle et grand public une gamme complète de services sûrs et fiables de livraisons sous 24h vers 99,7% des adresses professionnelles et résidentielles.
En ces temps difficiles où le besoin d’améliorer les performances des opérations se conjugue avec restrictions budgétaires, DX cherchait sur le marché une solution lui permettant d’accélérer le traitement de saisie de commandes. La trésorerie étant directement liée à la rapidité d'expédition de factures aux clients, DX s'est focalisé sur ce point.
ITESOFT.FreeMind Enterprise repose sur une technologie de nouvelle génération intégrant une base de connaissance dynamique et de multiples méthodes de reconnaissance et de classification. Alors que les solutions classiques proposées par les autres fournisseurs sont basées sur des modèles de lecture, DX a préféré se tourner vers une solution d'avenir moderne et souple qui saura accompagner la croissance de l'entreprise.

Contacts

onechocolate communications
Joelle Rousseau
Tél : +33 (0)1 41 31 75 07
joeller@onechocolatecomms.fr

Transformation d'une Direction Financière (H/F) - IDF

Logica Business Consulting  est l’entité Conseil du groupe Logica, acteur majeur des services informatiques réunissant 39 000 personnes à travers le monde. Son activité englobe conseil en management, intégration de technologies et externalisation.

Logica Business Consulting dispose d’un réseau de 3 500 consultants répartis sur les principaux pays européens. Ils s’engagent auprès de leurs clients dans la réussite de leur projet de transformation par une proximité avec tous les niveaux de l’entreprise associée à une combinaison unique d’expertises sectorielles, fonctionnelles et technologiques.

Logica Business Consulting est le 4e acteur Conseil en France avec 1 250 consultants.

Transformation d'une Direction Financière
- IDF -

L’objectif du stage

Participer à un projet de transformation de la fonction Finance chez un de nos clients.

Le contexte

Au sein d’une ligne d’activité de Conseil en management, couvrant l’ensemble des fonctions de l’entreprise, vous êtes rattaché à la division Performance de la fonction Finance (45 personnes). Vous contribuez aux projets de transformation nationaux et nternationaux de grandes entreprises de tous les secteurs(Banque / Assurance, Industrie, Energy & Utilities, Secteur Public …). Tout comme un Consultant junior, vous intégrez une équipe projet et vous êtes encadré par un Manager.

Votre mission

• Réaliser un benchmark et des diagnostics, en regard des best practices du marché et des standards applicables
• Définir et optimiser des organisations et des processus cibles (Order to Cash, Procure To Pay, Trésorerie, Budget…)
• Définir et mettre en oeuvre des indicateurs et des tableaux de bord de pilotage
• Définir et formaliser des principes de gestion ou de calcul des coûts
• Concevoir et déployer des systèmes d’informations financiers
• Structurer et animer un plan de transformation au sein d’une  entreprise
• Transformer des pratiques et accompagner au changement

Les + de ce stage :

1. Comprendre les enjeux du métier de Consultant
2. Acquérir des compétences fonctionnelles et sectorielles

Profil

Vous êtes étudiant(e) en dernière année d’une école d’ingénieurs, de commerce ou d’une université scientifique (Bac+4/5).